肝细胞癌患者化疗栓塞治疗的应用建议：评分系统的实用性？
Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?
作者信息
Adhoute Xavier, Penaranda Guillaume, Castellani Paul, Perrier Herve, Bourliere Marc
机构信息
Xavier Adhoute, Paul Castellani, Herve Perrier, Marc Bourliere, Department of Hepatology, Hopital Saint-Joseph, 13285 Marseille, France.
出版信息
World J Hepatol. 2015 Mar 27;7(3):521-31. doi: 10.4254/wjh.v7.i3.521.
Abstract
Several hepatocellular carcinoma (HCC) staging systems have been established, and a variety of country-specific treatment strategies are also proposed. The barcelona - clinic liver cancer (BCLC) system is the most widely used in Europe. The Hong Kong liver Cancer is a new prognostic staging system; it might become the reference system in Asia. Transarterial chemoembolization (TACE) is the most widely used treatment for HCC worldwide; but it showed a benefit only for intermediate stage HCC (BCLC B), and there is still no consensus concerning treatment methods and treatment strategies. In view of the highly diverse nature of HCC and practices, a scoring system designed to assist with decision making before the first TACE is performed or prior to repeating the procedure would be highly useful.
摘要
已经建立了几种肝细胞癌（HCC）分期系统，并且还提出了各种针对特定国家的治疗策略。巴塞罗那临床肝癌（BCLC）系统在欧洲使用最为广泛。香港肝癌是一种新的预后分期系统；它可能会成为亚洲的参考系统。经动脉化疗栓塞术（TACE）是全球范围内治疗HCC应用最广泛的方法；但它仅对中期HCC（BCLC B期）显示出益处，并且在治疗方法和治疗策略方面仍未达成共识。鉴于HCC及其治疗方法的高度多样性，设计一种评分系统以在首次进行TACE之前或重复该程序之前辅助决策将非常有用。
相似文献
1
Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?肝细胞癌患者化疗栓塞治疗的应用建议：评分系统的实用性？
World J Hepatol. 2015 Mar 27;7(3):521-31. doi: 10.4254/wjh.v7.i3.521.
2
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.经动脉化疗栓塞术在肝细胞癌治疗中的应用：巴塞罗那临床肝癌分期系统
World J Gastroenterol. 2015 Sep 28;21(36):10327-35. doi: 10.3748/wjg.v21.i36.10327.
3
Evaluation of different scoring systems for repeating Transarterial Chemoembolization in Egyptian patients with Hepatocellular Carcinoma.埃及肝细胞癌患者重复经动脉化疗栓塞术不同评分系统的评估
Rom J Intern Med. 2024 Aug 29;62(4):430-439. doi: 10.2478/rjim-2024-0028. Print 2024 Dec 1.
4
Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization.经动脉化疗栓塞术后中国患者香港肝癌分期系统的多中心评估
Cardiovasc Intervent Radiol. 2018 Dec;41(12):1867-1876. doi: 10.1007/s00270-018-2023-z. Epub 2018 Aug 2.
5
Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.经动脉化疗栓塞治疗肝细胞癌：慕尼黑-TACE评分的开发与外部验证
Eur J Gastroenterol Hepatol. 2018 Jan;30(1):44-53. doi: 10.1097/MEG.0000000000001005.
6
Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review.经动脉化疗栓塞与不可切除肝细胞癌：一项叙述性综述
Cureus. 2022 Aug 26;14(8):e28439. doi: 10.7759/cureus.28439. eCollection 2022 Aug.
7
Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma.经动脉化疗栓塞术作为射频消融术的替代方法用于治疗巴塞罗那临床肝癌分期0/A期的肝细胞癌。
Oncotarget. 2018 Apr 20;9(30):21560-21568. doi: 10.18632/oncotarget.25108.
8
Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.香港肝癌分期系统的建立与肝癌患者治疗分层策略。
Gastroenterology. 2014 Jun;146(7):1691-700.e3. doi: 10.1053/j.gastro.2014.02.032. Epub 2014 Feb 25.
9
Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.肝切除术与经肝动脉化疗栓塞术治疗巴塞罗那临床肝癌分期 B 期肝细胞癌的比较。
Hepatol Int. 2018 Sep;12(5):417-428. doi: 10.1007/s12072-018-9888-4. Epub 2018 Aug 2.
10
Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma.原发性肝细胞癌患者的肿瘤分期及初始治疗方式分布
Clin Transl Oncol. 2017 Jul;19(7):891-897. doi: 10.1007/s12094-017-1621-6. Epub 2017 Feb 3.
引用本文的文献
1
"Six-and-twelve" score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort.经动脉化疗栓塞术后肝细胞癌预后预测的“6分与12分”评分。来自法国多中心队列的深入分析。
World J Hepatol. 2020 Aug 27;12(8):525-532. doi: 10.4254/wjh.v12.i8.525.
2
A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.基于肝功能的肝细胞癌经动脉化疗栓塞术的差异风险评估与决策模型
BMC Cancer. 2020 Jun 1;20(1):504. doi: 10.1186/s12885-020-06975-2.
3
The Comprehensive Analysis of Efficacy and Safety of CalliSpheres Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study.367 例肝癌患者中 CalliSpheres 载药微球栓塞化疗的疗效和安全性综合分析：一项多中心队列研究。
Oncol Res. 2020 May 29;28(3):249-271. doi: 10.3727/096504019X15766663541105. Epub 2019 Dec 19.
4
Study to evaluate the immunomodulatory effects of radiofrequency ablation compared to surgical resection for liver cancer.研究评估与手术切除相比，射频消融对肝癌的免疫调节作用。
J Cancer. 2018 Aug 6;9(17):3187-3195. doi: 10.7150/jca.25084. eCollection 2018.
5
Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion.肝细胞癌的经动脉化疗栓塞术：肝功能及血管侵犯的影响
Br J Cancer. 2017 Feb 14;116(4):448-454. doi: 10.1038/bjc.2016.423. Epub 2017 Jan 26.
6
Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments.分期系统和预后评分在肝细胞癌治疗中的应用价值。
World J Hepatol. 2016 Jun 18;8(17):703-15. doi: 10.4254/wjh.v8.i17.703.
7
The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment: A Cohort Study in Taiwan.ART评分在选择经动脉化疗栓塞再治疗患者中的有效性：台湾的一项队列研究
Medicine (Baltimore). 2015 Nov;94(47):e1659. doi: 10.1097/MD.0000000000001659.
本文引用的文献
1
Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort.香港肝癌分期系统（HKLC）与巴塞罗那肝癌临床分期系统（BCLC）在欧洲肝癌队列中的实用性比较
J Hepatol. 2015 Feb;62(2):492-3. doi: 10.1016/j.jhep.2014.08.035. Epub 2014 Sep 4.
2
Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.经动脉化疗栓塞联合索拉非尼治疗不可切除肝细胞癌：一项系统评价与Meta分析
Mol Biol Rep. 2014 Oct;41(10):6575-82. doi: 10.1007/s11033-014-3541-7. Epub 2014 Aug 5.
3
Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.经动脉化疗栓塞（TACE）联合索拉非尼与 TACE 治疗中晚期肝细胞癌的疗效比较：一项荟萃分析。
PLoS One. 2014 Jun 19;9(6):e100305. doi: 10.1371/journal.pone.0100305. eCollection 2014.
4
Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization.经导管动脉化疗栓塞术后早期局部复发的危险因素及治疗结果
World J Gastroenterol. 2014 Jun 14;20(22):6995-7004. doi: 10.3748/wjg.v20.i22.6995.
5
Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.香港肝癌分期系统的建立与肝癌患者治疗分层策略。
Gastroenterology. 2014 Jun;146(7):1691-700.e3. doi: 10.1053/j.gastro.2014.02.032. Epub 2014 Feb 25.
6
Assessment for retreatment (ART) score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma.肝细胞癌患者重复经动脉化疗栓塞术的再治疗（ART）评分评估
Hepatology. 2014 Jun;59(6):2424-5. doi: 10.1002/hep.26760. Epub 2014 Apr 28.
7
The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE.ART 策略：ART 评分的序贯评估可预测经 TACE 再治疗的肝细胞癌患者的预后。
J Hepatol. 2014 Jan;60(1):118-26. doi: 10.1016/j.jhep.2013.08.022. Epub 2013 Sep 3.
8
A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer.用于接受经动脉栓塞治疗肝细胞癌患者的简单预后评分系统。
Ann Oncol. 2013 Oct;24(10):2565-2570. doi: 10.1093/annonc/mdt247. Epub 2013 Jul 14.
9
Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis.经动脉化疗栓塞治疗合并门静脉癌栓的肝细胞癌：一项荟萃分析。
BMC Gastroenterol. 2013 Apr 8;13:60. doi: 10.1186/1471-230X-13-60.
10
Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.索拉非尼联合肝动脉化疗栓塞治疗晚期肝细胞癌：222 例大样本多中心研究。
Ann Oncol. 2013 Jul;24(7):1786-1792. doi: 10.1093/annonc/mdt072. Epub 2013 Mar 18.
Zotero 插件